ARCHIVES

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

This article is from The Cancer Letter archive.

Vol. 25 No. 01 | January 8, 1999

Download PDF Visit The Full Archive

Related Articles

Drug Effectiveness Weakens After Three Years, Study Says

May 27, 2011

In a letter, ASCO reaffirms its views on oncology consolidation at FDA.

July 9, 2004

Interview With AACR’s Margaret Foti: “The Meeting Wouldn’t Have Been The Same.”

April 4, 2003

Molecular target Drug Discovery Grants; Unanimously Approved

July 2, 1999

Abstracts of Papers From ASCO Meeting

April 14, 1978

New Mechanism – Cancer Control Cooperative Groups – Under Consideration By NCUI For Regional Activities

May 11, 1984